Continuation of antibiotics is associated with failure of metronidazole for Clostridium difficile-associated diarrhea

Journal of Clinical Gastroenterology

Volumn 40, Issue 1, 2006, Pages 49-54

  Modena, Scott ^a   Gollamudi, Satya ^a   Friedenberg, Frank ^a  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

Antibiotics; Clostridium difficile; Colitis; Diarrhea; Metronidazole

Indexed keywords

METRONIDAZOLE; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA; COLITIS; CONFIDENCE INTERVAL; DIARRHEA; DISEASE SEVERITY; DRUG COST; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; LENGTH OF STAY; MALE; PRIORITY JOURNAL; RISK FACTOR; BACTERIAL INFECTION; CHI SQUARE DISTRIBUTION; HOSPITALIZATION; INTERVIEW; MICROBIOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PROSPECTIVE STUDY; TREATMENT FAILURE;

AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CHI-SQUARE DISTRIBUTION; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; FEMALE; HUMANS; INTERVIEWS; MALE; METRONIDAZOLE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT FAILURE;

EID: 33644978353     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000190761.80615.0f     Document Type: Article

References (33)

1. Fekety R. Guidelines for the Diagnosis and Management of Clostridium difficile-Associated Diarrhea and Colitis. Am J Gastroenterol. 1997;92:739-750.
2. Bartlett J. Antibiotic-associated diarrhea. N Engl J Med. 2002;346:334-339.
3. Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA. 1993;269:71-75.
4. Kelly CP, Pothoulakis C, Lamont JT. Clostridium difficile colitis. N Engl J Med. 1994;330:257-262.
5. Bartlett JG. Antimicrobial agents implicated in Clostridium difficile toxin-associated diarrhea or colitis. Johns Hopkins Med J. 1981;149:6-9.
6. Gerding DN. Disease associated with Clostridium difficile infection. Ann Intern Med. 1989;110:255-257.
7. Friedenberg F, Fernandez A, Kaul Vivek, et al. Intravenous metronidazole for the treatment of clostridium difficile colitis. Dis Colon Rectum. 2001;44:1176-1180.
8. Yassin SF, Young-Fadok TM, Zein N. et al. Clostridium difficile-associated diarrhea and colitis. Mayo Clin Proc. 2001;76:725-730.
9. Mitty R, Lamont JT. Clostridium difficile diarrhea: pathogenesis, epidemiology, and treatment. Gastroenterologist. 1994;2:61-69.
10. Hospital Infection Control Advisory Committee. Recommendations for preventing the spread of vancomycin-resistant enterococci. Am J Infect Control. 1995;23:87-94.
11. Surawicz C. Treatment of recurrent Clostridium difficile-associated disease. Nat Clin Prac. 2004;1:32-37.
12. Nair S, Yadav D, Corpuz M, et al. Clostridium difficile colitis: factors influencing treatment failure and relapse - a prospective evaluation. Am J Gastroenterol. 1998;93:1873-1876.
13. Fernandez A, Anand G, Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J Clin Gastroenterol. 2004;38:414-418.
14. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920-924.
15. Fekety R, Mcfarland L, Surawicz C, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double blinded trial. Clin Infect Dis. 1997;24:324-333.
16. Wenisch C, Parschalk B, Hasenhundl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis. 1996;22:813-818.
17. Teasley DG, Olson MM, Gebhard RL, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile associated diarrhea and colitis. Lancet. 1983;2:1043-1046.
18. Olson M, Shanholtzer C, Lee James, et al. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol. 1994;15:371-381.
19. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991-2003: a changing pattern of disease severity. Can Med Assoc J. 2004;171:466-472.
20. Brazier J, Fawley W, Freeman J, et al. Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother. 2001;48:741-742.
21. Wong SS, Woo PC, Luk WK, et al. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis. 1999;34:1-6.
22. Pelaez T, Alcala R, Alonso R. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother. 2002;46:1647-1650.
23. Drummond LJ, McCoubrey J, Smith DG. et al. Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18 month period. J Med Microbiol. 2003;52:259-263.
24. Cheng SH, Chu FY, Lo SH, et al. Antimicrobial susceptibility of Clostridium difficile by E test. J Microbiol Immunol Infect. 1999;32:116-120.
25. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut. 1986;27:1169-1172.
26. Kyne L, Hamel MB, Polavaram R, et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34:346-353.
27. Macgowan AP, Feeney R, Brown I, et al. Health care resource utilization and antimicrobial use in elderly patients with community-acquired lower respiratory tract infection who develop Clostridium difficile-associated diarrhea. J Antimicrob Chemother. 1997;39:537-541.
28. Kofsky P, Rosen L, Reed J, et al. Clostridium difficile: a common and costly colitis. Dis Colon Rectum. 1991;34:244-248.
29. Wilcox MH, Cunniffe JG, Trundle C, et al. Financial burden of hospital-acquired Clostridium difficile infection. J Hosp Infect. 1996;34:23-30.
30. Leroi MJ, Siarakas S, Gottlieb T. E Test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin and linezolid. Eur J Clin Microbiol Infect Dis. 2002;21:72-74.
31. Marchese A, Salerno A, Pesce A, et al. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy. 2000;46:253-266.
32. Kreutzer E, Milligan F. Treatment of antibiotic-associated pseudomembranous colitis with cholestyramine resin. Johns Hopkins Med J. 1978;143:67-72.
33. Taylor N, Bartlett J. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis. 1980;141:92-97.